Lignes directrices provisoires actualisées 7 juin 2016
Version Révisée SEPTEMBRE 2016
Petersenet al.International Journal of Mental Health Systems2011,5:8http://www.ijmhs.com/content/5/1/8
This document has been developed as a guide to allinstitutions producing health care waste in planning and implementation of interventions that will reduce mismanagement of hazardous waste in Zambia.The National Health-Care Waste Management Plan for 2015 to 2019 provides an overv...iew of the situation analysis, the proposed activities and the health care facility waste generating processes in Zambia and presents options for minimizing health-care waste generation through source reduction. The hazardous wastes generated by health care facilities are a challenge in Zambia as handling, storage, transportation and final disposal leaves much to be desired.
more
Moving towards equity and quality
Recommendations for Tuberculosis Screening Before Initiation of TNF-α-Inhibitor Treatment in Rheumatic Diseases
Diel R et al. Empfehlungen für das Tuberkulosescreening vor Gabe von TNF-α-Inhibitoren… Pneumologie 2009; 63: 329–334
- Build community resilience to coastal hazards by improving capacity of inclusive disaster management systems.
- Reduce the mortality rate of persons with disabilities in situations of risk.
- Raise awareness about inclusive policies, practices and disaster risk reduction strategies that ...address the accessibility of communication, shelter, transportation and early warning systems.
- Foster collaboration between disaster preparedness organizations, broadcasters and organizations of persons with disabilities to mainstreaming disability issues in disaster risk reduction strategies.
- Build the capacity of disaster management organizations, governments, broadcasters and built environment practitioners by providing technical specifications on accessible communications and the design of accessible shelters and the built environment.
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Petersen et al. Int J Ment Health Syst (2016) 10:30 DOI 10.1186/s13033-016-0060-z
Health Systems for Outcomes Publication | Using qualitative data from Rwanda, this study focuses on four institutional factors that affect health worker performance and career choice: incentives, monitoring arrangements, professional norms and health workers’ intrinsic motivation. It also provides... illustrations of three institutional innovations that work, at least in the context of Rwanda: performance pay, the establishment of community health workers and increased attention to the training of health workers.
more
The purpose of the PAS III is to guide Pakistan’s overall national response for HIV and AIDS through 2020, through focused interventions with set targets, costs, roles and responsibilities. The successful implementation of PAS III involves multiple stakeholders to achieve priority outcomes outline...d in the Strategy. The Strategy focuses on allocating limited resources to scale up high-impact, high-value interventions such as HTC and treatment to reduce AIDS related deaths and new HIV infections. Priorities in the PAS III have been identified to ensure maximum impact in reducing new infections, especially among key populations, improving treatment uptake and retention, and improving the quality of life of people living with HIV and AIDS in the context of limited financial and human resources.
more
WHO Secretariat Information paper July 2016